Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

BACKGROUND: The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/PD‐L1 monotherapy in non‐small cell lung cancer (NSCLC) patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Tozuka, Takehiro, Kitazono, Satoru, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Uematsu, Shinya, Yoshizawa, Takahiro, Hasegawa, Tsukasa, Ariyasu, Ryo, Uchibori, Ken, Yanagitani, Noriko, Horai, Takeshi, Seike, Masahiro, Gemma, Akihiko, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471023/
https://www.ncbi.nlm.nih.gov/pubmed/32657011
http://dx.doi.org/10.1111/1759-7714.13557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471023/
https://www.ncbi.nlm.nih.gov/pubmed/32657011
http://dx.doi.org/10.1111/1759-7714.13557

Ejemplares similares